How Can We Unlock the Next Wave of GPCR Therapeutics?
As drug developers look beyond GLP-1 to identify the next breakthrough GPCR therapeutic, the field is being transformed by advances in AI, structural biology, screening technologies, and signaling science. The 6th GPCRs-Targeted Drug Discovery Summit brings together the scientists leading that transformation to:
- Unlock novel GPCR biology through advances in orphan receptor discovery, target validation, and emerging GPCR targets.
- Accelerate discovery programs with AI-enabled workflows, structure-guided drug design, advanced screening platforms, and translational pharmacology strategies.
- Explore the future of GPCR therapeutics across small molecules, antibodies, peptides, obesity, oncology, autoimmune disease, CNS, and pain.
Join the dedicated community of GPCR researchers shaping the future of drug discovery and leave equipped with the insights, connections, and strategies needed to accelerate your next breakthrough.
What To Expect?
Go Beyond GLP-1 to Identify the Next GPCR Breakthrough
Discover where the industry's next major scientific and commercial opportunities are emerging across novel targets, transformative technologies, and next-generation therapeutics.
Featuring Insights from:
Eli Lilly • Atrogi • Kainova Therapeutics
Evaluate What AI & ML Has Actually Delivered for GPCR Discovery
Move beyond AI hype and benchmark how leading organizations are leveraging machine learning and computational approaches to improve discovery outcomes, candidate quality, and decision-making.
Featuring insights from:
LEMBAS • Biagon Inc • Recursion Pharmaceuticals
Unlock the Next Generation of GPCR Targets
Explore emerging approaches to orphan receptor discovery, target validation, super-dark GPCR biology, and signaling science to expand the future landscape of druggable receptors.
Featuring insights from:
University of Miami • Alphamol • Duke University
Advance Emerging Modalities Beyond Traditional Small Molecules
Compare the latest progress in antibodies, peptides, biologics, and multi-receptor therapeutics to determine the optimal modality for future GPCR programs.
Featuring insights from:
Abalone Bio • Confo Therapeutics • SelekTx Precision Biologics
Explore the Full Event Guide
- Explore the complete 2027 agenda, featuring a dedicated focus day deep dive into emerging discovery technologies alongside two days of cutting-edge GPCR science.
- Preview exclusive sessions from Eli Lilly, Pfizer, Roche, Recursion Pharmaceuticals, Alphamol, and University of Miami.
- Discover how the industry is tackling GPCR discovery's biggest challenges, from target validation and signaling biology to AI accountability and biased agonism.
- See who you'll be networking with, including scientific decision-makers from leading pharma, biotech, and academic organizations.
- Identify the sessions, speakers, and networking opportunities most relevant to your programs before you attend.
Attending Companies Include
Explore the Agenda
Discover the latest advances in AI-enabled discovery, target validation, signaling biology, and emerging GPCR therapeutics across three days of scientific discussion.
Partner With Us
Showcase your expertise to a highly targeted audience of scientists and decision-makers actively seeking technologies, services, and partners to accelerate GPCR discovery.
Join the GPCR Community
Connect with leading pharma, biotech, and academic experts tackling the biggest challenges and opportunities shaping the future of GPCR drug discovery.